Leerink Partners analyst Daina Graybosch downgraded the rating on Innate Pharma to a Hold today, setting a price target of $2.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Daina Graybosch’s rating is based on several critical factors impacting Innate Pharma’s outlook. The company’s decision to focus heavily on an antibody-drug conjugate (ADC) strategy, while sidelining their NK cell engager therapeutic platform, raises concerns due to the uncertain timeline for achieving clinical proof-of-concept results. This strategic shift, coupled with the inability to secure a partner for the co-development of lacutamab, adds to the uncertainty surrounding the company’s future prospects.
Additionally, financial challenges loom as Innate Pharma struggles with financing options for a Phase 3 study of lacutamab, which is crucial for accelerated approval. The company’s recent announcement of a 30% workforce reduction and changes in key leadership positions further contribute to the cautious outlook. Although there is potential in their lead ADC candidate, Nectin-4 targeting IPH4502, the anticipated updates may not be sufficient to generate significant market interest, leading to a Hold rating for the stock.
According to TipRanks, Graybosch is an analyst with an average return of -13.4% and a 35.66% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Summit Therapeutics.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.